Depyrogenated sterile empty vials market trends are anticipated to witness a significant change over the coming years owing to increasing awareness among people about HIV and other infectious diseases. Several regions in the world are striving to bring the spread of HIV/AIDS under control. Governments are taking various measures to eradicate the spread of such infectious diseases and investing in research and development activities across the globe, which will substantially impel the industry outlook.
A worldwide increase in incidences of infectious diseases is expected to enhance depyrogenated sterile empty vials market growth. In 2017, there were approximately 36.9 million people across the globe living with HIV/AIDS – the number reached nearly 37.9 million in 2018. About 23.3 million people were going through antiretroviral therapy by the end of 2018. Approximately, 62% of people enduring HIV were getting treated with antiretroviral medication in the same year. Upsurge in awareness and treatment is likely to augment depyrogenated sterile empty vials market size over 2019-2025.
Get a Sample Copy of this Report:@ https://www.gminsights.com/request-sample/detail/3058
Asia Pacific region had been estimated to have 5.2 million people living with HIV in 2017. China, India and Indonesia account for almost three-quarters of the total number of people living with HIV in the region. In 2017, 74% of people living with HIV in APAC region were aware of their infection.
Among those diagnosed with HIV, 71% were on treatment and 85% were virally suppressed. Around 2.7 million people living with HIV in the region were accessing antiretroviral treatment (ART) in 2017, up from 900,000 in 2010. Upsurge in number of patients being treated to control HIV will contribute considerable proceeds to depyrogenated sterile empty vials industry by 2025.
APAC depyrogenated sterile empty vials industry accounted for about 24% revenue share in the year 2018 and is projected to register a significant increase by 2025.
Many R&D activities have been initiated to cure infectious diseases like HIV. For instance, Merck had announced the results from a phase 2B clinical trial of investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI), islatravir (MK-8591), for the treatment of HIV-1. A persistent necessity has been observed for additional efficient therapeutic regimens for the treatment of people enduring HIV-1, and islatravir has been affirmed for further trials.
Based on the Phase 2B data, the company has planned to start a phase 3 trial to evaluate islatravir in combination with doravirine. The phase 3 trial will be studied across diverse patient populations to report the evolving requirements of people living with HIV-1. Such R&D activities are also being promoted by governments to improve national health status which may influence depyrogenated sterile empty vials market growth.
Browse Report Summary @ https://www.gminsights.com/industry-analysis/depyrogenated-sterile-empty-vials-market
The research-based pharmaceutical industry currently spends more than $149.8 billion on R&D per year. In 2015, 56 new medicines were rolled out, while currently over 7,000 compounds are at different levels of development globally. In 2014, there were 401 drugs in the pipeline for diabetes and 208 drugs in development for HIV/AIDS. Currently, IFPMA members have 119 ongoing R&D projects related to neglected tropical diseases. A huge number of clinical studies has led to increased injectables that will further augment depyrogenated sterile empty vials market growth.
Most clinical studies use more than 20 ml vials. In this context, it is prudent to mention that more than 20 ml product segment in depyrogenated sterile empty vials market was evaluated at more than $1.5 million in 2018. Current trends indicate that the segment will experience enormous growth over forecast period.
Instances of growth in APAC depyrogenated sterile empty vials market can be cited through the industry scenario in India. The Indian government has regulated policies which aim at promoting both public and private sector involvement in the R&D practice. With more and more multinational pharmaceutical companies setting up their R&D centers in India, the sector has seen an uptrend in investments in recent years.
In the year 2015, India was ranked as the country with the sixth largest annual R&D spending in the world, responsible for 3.53 percent of global R&D outgoings. R&D spending in India is anticipated to grow from 0.9 per cent to 2.4 percent of the country’s GDP from 2014 to 2034. Increasing demand and investments in R&D activities in pharmaceutical sector is anticipated to drive depyrogenated sterile empty vials industry in the times to come.
Related Insightful [email protected]